INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial.

Find People
Find Everything
About This Site
Edit My Profile
Login to Profiles
DIRECT2Experts
Help / FAQ

History

5' Flanking Region

INST OX-05-024: first

Announcement

You can now add alternative names! Click here to add other names that you've published under.

INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial.

Patt YZ, Murad W, Fekrazad MH, Baron AD, Bansal P, Boumber Y, Steinberg K, Lee SJ, Bedrick E, Du R, Lee FC. INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial. Cancer Med. 2017 Sep; 6(9):2042-2051.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Bile Duct Neoplasms
Carcinoma, Hepatocellular
Deoxycytidine
Female
Humans
Liver Neoplasms
Male
Middle Aged
Organoplatinum Compounds
Prospective Studies
Survival Analysis
Treatment Outcome

authors with profiles

Ruofei Du